PresentationThomas LarsenHead of Investor Relations Good afternoon and good morning, depending on where you are, and welcome to the Sanofi's first year-end late-stage pipeline review. I'm Thomas Kudsk Larsen from the Investor Relations team and I'm pleased to see so many people on the call today. Before we get started, I want to thank Alizé in the IR team for leading the work on today's call. I also want to remind everyone that our focus is on the clinical and regulatory aspects of the mid- and late-stage ...